In recent years, several genetic studies have associated the loss of CYLD functionality with the dysregulation of NF-κB, JNK, c-Myc or Akt [10–12] and the development of different types of cancers of high prevalence in the population (multiple myeloma, hepatocarcinomas, lung, breast and gastric cancers, etc.)[13]. This evidence concerns the gene CYLD and cancer.